NEW YORK, Aug. 5 (GenomeWeb News) - Epoch Biosciences reported flat revenues for the second quarter today, amid widened net losses.
The company's revenues totaled $2.5 million for both this quarter and the second quarter of 2002.
Net losses for the Bothell, Wash.-based company widened to $3.1 million, compared to $1.2 million for the year-ago quarter.
R&D expenses were also flat at $1.1 million, compared to $1.1 million for the second quarter of 2002.
As of June 30, Epoch had $4.6 million in cash and cash equivalents.